Log In
BCIQ
Print this Print this
 

AMG 282, RG6149

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionAntibody that inhibits the binding of interleukin-33 (IL-33; NF-HEV) to interleukin-1 (IL-1) receptor-like 1 (IL1RL1; ST2)
Molecular Target Interleukin-33 (IL-33) (NF-HEV) ; Interleukin-1 (IL-1) receptor-like 1 (IL1RL1) (ST2) (IL-33R)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAsthma
Indication DetailsTreat mild atopic asthma
Regulatory Designation
PartnerGenentech Inc.;
Roche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/28/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today